Pharmacokinetics and pharmacodynamics of topotecan in patients with advanced cancer.

  title={Pharmacokinetics and pharmacodynamics of topotecan in patients with advanced cancer.},
  author={Louise B. Grochow and Eric K. Rowinsky and Richard Johnson and Susan M. Ludeman and Scott H. Kaufmann and Francis L. McCabe and Brian Richard Smith and L A Hurowitz and A Delisa and Ross C. Donehower},
  journal={Drug metabolism and disposition: the biological fate of chemicals},
  volume={20 5},
Topotecan, a semisynthetic water-soluble analog of camptothecin, is the first topoisomerase I-directed drug to enter clinical trial in the United States in over 20 yr. In this study, 30-min infusions of topotecan were administered daily for 5 days every 3 weeks at doses ranging from 0.5 to 2.5 mg/m2. Topotecan is reversibly hydrolyzed in a pH-dependent reaction in aqueous solutions to the ring-open hydroxy acid. The disposition of the closed ring lactone has been studied in 26 patients, and the… CONTINUE READING

From This Paper

Topics from this paper.


Publications citing this paper.
Showing 1-10 of 37 extracted citations

Similar Papers

Loading similar papers…